Phase 3 trials examining new treatments for metastatic hormone-sensitive prostate cancer (mHSPC) can take up to a decade to complete when overall survival (OS) is used as the primary end point due to the large trial sizes and extended follow-up periods required of OS measurement. While new research, including the CHAARTED trial, has aimed to expand the survival rates of patients with mHSPC, the 5-year OS rate of metastatic prostate cancer remains at 30%. ...
mHSPC
Advertisement
Latest News
The PNI is commonly used as a prognostic factor for malignant tumors, but its potential use for prostate cancer is unknown.
Patients with a suboptimal PSA response who are administered intensified ADT often experience worse survival outcomes.
A meta-analysis sought to determine the efficacy of systemic therapies in patients with PCa and poor performance status.
Updated AUA/SUO Guideline on Advanced Prostate Cancer Offers New Recommendations on Imaging, Testing
The updated guideline emphasizes the use of PSMA PET for periodic staging, as well as the use of ADT.Results from the CHAARTED trial demonstrated that ADT and docetaxel improves OS and QOL at 12 months compared with ADT alone.
Researchers studied several trials including LATITUDE and STAMPEDE to find similar characteristics among ARAT treatments.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.